1/171
Looks like no tags are added yet.
what factors do warfarin inhibit
-VII
-X
-IX
-II
what factors do rivaroxaban inhibit
Xa
what factors do apixaban inhibit
Xa
what factors do edoxaban inhibit
Xa
what factors do fondaparinux inhibit
Xa
what factors do enoxaparin inhibit
Xa
what factors do delteparin inhibit
Xa
what factors do bivalirubin inhibit
IIa
what factors do argatroban inhibit
IIa
what factors do dabigatran inhibit
IIa
derivative of heparin
fondaparinux
examples of low molecular weight heparin (LMWH)
Enoxaparin
Dalteparin
direct thrombin inhibitors
-Dabigatran
-bivalirubin
-argatroban
what drug is a family of sulfated glycosaminoglycans
heparin
what drug is extracted from beef lung or hog intestine
heparin
what drugs are isolated from standard heparin by gel filtration chromatography
low molecular weight heparins
heparin MOA
inhibits coagulation by activating antithrombin, antithrombin inhibits thrombin and other serine proteases by binding to the active serine site
LMWHs increase the action of ______ on factor Xa but not its action on thrombin
antithrombin
clinical use of heparin
-venous thrombosis, PE
-unstable angina or MI
-during or after coronary balloon angioplasty or stent placement
-disseminated intravascular coagulation
what is the drug of choice for anticoagulation during pregnancy
heparin
adverse effect of heparin
-bleeding
-heparin induced thrombocytopenia
antidote for heparin
protamine sulfate
adverse effects of protamine
-anaphylaxis
-hypotension
-pulmonary vasoconstriction
MOA of heparin induced thrombocytopenia (HIT)
development of an antibody against complexes of heparin with platelet factor 4 which activate platelet and thrombin generation
treatment of HIT
-discontinue heparin
-treat with bivalirudin, argatroban
MOA of LMWH
increase the inhibitory action of antithrombin on factor Xa but not its action on thrombin
clinical use of LMWH
-DVT
-thromboembolism
-unstable angina
-hip replacement
-pregnant
MOA of fondaparinux
indirect factor Xa inhibitor
clinical use of fondaparinux
- thromboprophylaxis
- PE
- DVT
adverse effects of fondaparinux
bleeding, thrombocytopenia
MOA of bivalirudin
-recombinant derivative of hirudin
-binds irreversibly both to the fibrin binding and catalytic sites on thrombin, inhibiting thrombin activity
clinical use of bivalirudin
alternative to heparin in patients undergoing coronary angioplasty with HIT history
adverse effect of bivalirudin
bleeding
MOA of argatroban
synthetic direct thrombin inhibitor that binds irreversibly to the catalytic site of thrombin
Clinical use of Argatroban
alternative to bivalirubin for prophylaxis or treatment of patients with or at risk of developing HIT
adverse effects of argatroban
bleeding
what inhibits vitamin K reductase leading to anticoagulation effects
warfarin
what factor has the longest half life
Factor II
clinical use of warfarin
-DVT or PE following heparin
-prevent stroke or systemic embolism
adverse effects of warfarin
-bleeding
-skin necrosis
treatment of bleeding with warfarin
-test INR
-withhold or reduce warfarin
-administration of vitamin K
-infusion of fresh plasma or coagulation factor concentrates
CYP2C9 inducers that interact with warfarin
barbiturates, carbamazepine, rifampin, phenytoin
CYP2C9 inhibitors that interact with warfarin
amiodarone, azole antifungals, disulfiram, metronidazole, fluoxetine
interactions with warfarin
-vitamin K availability
-low coagulation factors
-alcohol
-aging
MOA of rivaroxaban
inhibits factor Xa, results in reduced thrombin generation, suppresses platelet aggregation and fibrin formation
interaction with rivaroxaban
ketoconazole, itraconazole, ritonavir, and clarithromycin
clinical use of rivaroxaban
-DVT
-PE
-prevention of thrombosis in Afib, knee replacement surgery
MOA of dabigatran
converted by plasma esterase to active dabigatran, reversible direct thrombin inhibitor
clinical use of dabigatran
-DVT
-PE
-prevent stroke or systemic embolism
adverse effects of dabigatran
bleeding and GI upset
antidote of dabigatran
Idarucizumab
Cox1 inhibitor
aspirin
P2Y12 inhibitors
-Clopidogrel
-Prasugrel
-Ticagrelor
-cangrelor
fibrinogen receptor (GPIIb/IIIa) antagonists
-abciximab
-eptifibatide
-tirofiban
MOA of aspirin
blockade of thromboxane production through irreversible blocking of cyclooxygenase
clinical use of aspirin
-prevent thrombosis that lead to MI, ischemic stroke, peripheral vascular thrombosis
-undergoing coronary artery intervention
-analgesic, antipyretic, treatment of rheumatoid disease
MOA of dipyridamole
Inhibits the uptake of adenosine into platelets and increases cAMP levels, which inhibits platelet aggregation
clinical use of dipyridamole
-used in combination with warfarin to decrease thrombosis in patients after artificial heart valve replacement
-used with aspirin for stroke prevention
-vasodilator
true or false: dipyridamole is typically given on its own
false
adverse reaction of dipyridamole
headache, palpitation
clopidogrel is activated into its active form by what
CYP2C19
MOA of clopidogrel
prodrug that requires activation by CYP2C19 in liver with slow onset action and slow offset action. Active clopidogrel irreversibly inhibits ADP P2Y12 receptor, blocking ADP-induced platelet aggregation.
clinical use of clopidogrel
-after angioplasty with aspirin
-recent stroke or MI, peripheral arterial disease, acute coronary syndrome
adverse effects of clopidogrel
-bleeding
-thrombotic thrombocytopenia purpura (TTP)
what is TTP treated with
plasma replacement and caplacizumab
difference of prasugrel from clopidogrel
-more rapid onset of action
-greater inhibition of ADP induced platelet aggregation
-higher risk of bleeding
MOA of ticagrelor
An oral, reversible, non-thienopyridine antagonist of the P2Y12 receptor that provides more rapid and predictable levels of antiplatelet therapy
clinical use of ticagrelor
-acute coronary syndrome
-patients undergoing coronary intervention
MOA of cangrelor
reversible inhibitor of P2Y12
Clinical use of cangrelor
patients undergoing percutaneous coronary intervention
MOA of aciximab
Fab fragment of a humanized monoclonal antibody against the GP IIb/IIIa receptor complex and inhibits platelet aggregation
clinical use of aciximab
patients undergoing percutaneous coronary intervention and acute coronary syndrome
adverse effects of aciximab
bleeding and thrombocytopenia
MOA of eptifibatide
cyclic peptide inhibitor of the fibrinogen binding site on GPIIb/IIIa
MOA of tirofiban
small-molecule inhibitor of GPIIb/IIIa
fibrinolytics
-Alteplase
-Tenecteplase
MOA of alteplase
recombinant tissue plasminogen activator (t-PA), initiates local fibrinolysis by binging to fibrin in a thrombus and converts entrapped plasminogen to plasmi
indications of alteplase
-Acute coronary arterial thrombosis
-Acute pulmonary thromboembolism
-Acute ischemic stroke
-Central venous catheter clearance
half life of alteplase
5 minutes
adverse effects of alteplase
- bleeding
- arrhythmias during coronary arterial thrombosis
MOA of tenecteplase
modified form of t-PA, binds to the fibrin component of the thrombus and selectively converts thrombus-bound plasminogen to plasmin, which degrades the fibrin matrix of the thrombus
indication of tenecteplase
acute MI
the half life of tenecteplase is ____ compared to alteplasse
increased
adverse effects of tenecteplase
bleeding, arrhythmias
Anti-fibrinolytics
aminocaproic acid
tranexamic acid
MOA of aminocaproic acid
lysine analog that competes for lysine binding sites on plasminogen and plasmin, thus blocking the interaction of plasmin with fibrin
clinical use of aminocaproic acid
- fibrinolytic bleeding (post operative, hemorrhagic conditions)
- overdose of thrombolytic agents
side effects of aminocaproic acid
- myopathy, muscle necrosis
- intravascular thrombosis
- hypotension
- abdominal discomfort
-rhabdomylosis
what does mutations in LDL-receptor gene lead to
familial hypercholesterolemia
bile acid sequestrants
-cholestyramine
-colesevelam
-colestipol
LPL activator
niacin
HMG-CoA reductase inhibitors
-atorvastatin
-lovastatin
-pravastatin
-rosuvastatin
-simvastatin
Cholesterol absorption (NPC1L1) inhibitor
Ezetimibe
Fibric acid (PPAR agonist)
Fenofibrate
Gemfibrozil
PCSK9 inhibitors
-Alirocumab
-Evolocumab
-Inclisiran
-lerodalcibep
-enlicitide
MTTP inhibitor
Lomitapide
Omega-3 Fatty Acids
icospent ethyl
ANGPTL3 inhibitor
Evinacumab
ATP Citrate Lyase (ACL) Inhibitor
bempedoic acid
ApoC-III inhibitors
-plozasiran
-olezarsen